Werewolf Therapeutics stock hits 52-week low at $0.85

In a challenging year for biotech firms, Werewolf Therapeutics, Inc. (HOWL) stock has reached a new 52-week low, touching down at $0.85. InvestingPro data shows the stock is currently trading at $0.82, with technical indicators suggesting oversold conditions. Despite analyst price targets ranging from $4 to $15, the company’s market capitalization has shrunk to just $36.76 million. This latest price point underscores a period of significant decline for the company, which has seen its stock value plummet by 86.17% over the past year. Investors have been wary of the sector due to various factors, including regulatory hurdles and a shift in market sentiment away from high-risk growth stocks. Werewolf Therapeutics, which specializes in oncology treatments, has not been immune to these industry-wide pressures, resulting in a stark decrease in its market valuation. According to InvestingPro’s comprehensive analysis, the company maintains strong liquidity with a current ratio of 7.45 and holds more cash than debt on its balance sheet. Discover more insights with InvestingPro’s detailed research report, available along with 12 additional ProTips for HOWL.

In other recent news, Werewolf Therapeutics, Inc. announced changes to its board of directors. Dr. Derek DiRocco has resigned from the board, effective at the company’s annual stockholders’ meeting in 2025, with no disagreements cited as the reason for his departure. Concurrently, Werewolf Therapeutics appointed Dr. Anil Singhal as a new Class I director, who will also serve on the company’s Audit Committee. Dr. Singhal brings over three decades of experience in biopharmaceutical research and development, having held leadership positions at Trishula Therapeutics, Adicet Bio, and AbbVie (NYSE:ABBV). He also serves on the board of TriSalus Inc., a publicly traded biotechnology company. Dr. Singhal’s educational background includes a Ph.D. in Biochemistry from Rutgers University and an MBA from the University of Washington. As part of his compensation, Dr. Singhal will receive an annual cash fee, expense reimbursements, and an option to purchase 45,000 shares of Werewolf Therapeutics’ common stock, vesting over three years. These developments were disclosed in a press release by Werewolf Therapeutics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.